Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays

A. Aleman, L. Adrien, L. Lopez-Serra, C. Cordon-Cardo, M. Esteller, T. J. Belbin, M. Sanchez-Carbayo

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

CpG island arrays represent a high-throughput epigenomic discovery platform to identify global disease-specific promoter hypermethylation candidates along bladder cancer progression. DNA obtained from 10 pairs of invasive bladder tumours were profiled vs their respective normal urothelium using differential methylation hybridisation on custom-made CpG arrays (n=12 288 clones). Promoter hypermethylation of 84 clones was simultaneously shown in at least 70% of the tumours. SOX9 was selected for further validation by bisulphite genomic sequencing and methylation-specific polymerase chain reaction in bladder cancer cells (n=11) and primary bladder tumours (n=101). Hypermethylation was observed in bladder cancer cells and associated with lack of gene expression, being restored in vitro by a demethylating agent. In primary bladder tumours, SOX9 hypermethylation was present in 56.4% of the cases. Moreover, SOX9 hypermethylation was significantly associated with tumour grade and overall survival. Thus, this high-throughput epigenomic strategy has served to identify novel hypermethylated candidates in bladder cancer. In vitro analyses supported the role of methylation in silencing SOX9 gene. The association of SOX9 hypermethylation with tumour progression and clinical outcome suggests its relevant clinical implications at stratifying patients affected with bladder cancer.

Original languageEnglish (US)
Pages (from-to)466-473
Number of pages8
JournalBritish Journal of Cancer
Volume98
Issue number2
DOIs
StatePublished - Jan 29 2008

Fingerprint

Urinary Bladder Neoplasms
DNA
Methylation
Epigenomics
Clone Cells
Urothelium
Neoplasms
CpG Islands
Gene Silencing
Gene Expression
Polymerase Chain Reaction
Survival

Keywords

  • Bladder cancer
  • CpG arrays
  • Methylation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Aleman, A., Adrien, L., Lopez-Serra, L., Cordon-Cardo, C., Esteller, M., Belbin, T. J., & Sanchez-Carbayo, M. (2008). Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays. British Journal of Cancer, 98(2), 466-473. https://doi.org/10.1038/sj.bjc.6604143

Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays. / Aleman, A.; Adrien, L.; Lopez-Serra, L.; Cordon-Cardo, C.; Esteller, M.; Belbin, T. J.; Sanchez-Carbayo, M.

In: British Journal of Cancer, Vol. 98, No. 2, 29.01.2008, p. 466-473.

Research output: Contribution to journalArticle

Aleman, A, Adrien, L, Lopez-Serra, L, Cordon-Cardo, C, Esteller, M, Belbin, TJ & Sanchez-Carbayo, M 2008, 'Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays', British Journal of Cancer, vol. 98, no. 2, pp. 466-473. https://doi.org/10.1038/sj.bjc.6604143
Aleman, A. ; Adrien, L. ; Lopez-Serra, L. ; Cordon-Cardo, C. ; Esteller, M. ; Belbin, T. J. ; Sanchez-Carbayo, M. / Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays. In: British Journal of Cancer. 2008 ; Vol. 98, No. 2. pp. 466-473.
@article{53f5dd279e6a45d48e01b34796eaa28e,
title = "Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays",
abstract = "CpG island arrays represent a high-throughput epigenomic discovery platform to identify global disease-specific promoter hypermethylation candidates along bladder cancer progression. DNA obtained from 10 pairs of invasive bladder tumours were profiled vs their respective normal urothelium using differential methylation hybridisation on custom-made CpG arrays (n=12 288 clones). Promoter hypermethylation of 84 clones was simultaneously shown in at least 70{\%} of the tumours. SOX9 was selected for further validation by bisulphite genomic sequencing and methylation-specific polymerase chain reaction in bladder cancer cells (n=11) and primary bladder tumours (n=101). Hypermethylation was observed in bladder cancer cells and associated with lack of gene expression, being restored in vitro by a demethylating agent. In primary bladder tumours, SOX9 hypermethylation was present in 56.4{\%} of the cases. Moreover, SOX9 hypermethylation was significantly associated with tumour grade and overall survival. Thus, this high-throughput epigenomic strategy has served to identify novel hypermethylated candidates in bladder cancer. In vitro analyses supported the role of methylation in silencing SOX9 gene. The association of SOX9 hypermethylation with tumour progression and clinical outcome suggests its relevant clinical implications at stratifying patients affected with bladder cancer.",
keywords = "Bladder cancer, CpG arrays, Methylation",
author = "A. Aleman and L. Adrien and L. Lopez-Serra and C. Cordon-Cardo and M. Esteller and Belbin, {T. J.} and M. Sanchez-Carbayo",
year = "2008",
month = "1",
day = "29",
doi = "10.1038/sj.bjc.6604143",
language = "English (US)",
volume = "98",
pages = "466--473",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays

AU - Aleman, A.

AU - Adrien, L.

AU - Lopez-Serra, L.

AU - Cordon-Cardo, C.

AU - Esteller, M.

AU - Belbin, T. J.

AU - Sanchez-Carbayo, M.

PY - 2008/1/29

Y1 - 2008/1/29

N2 - CpG island arrays represent a high-throughput epigenomic discovery platform to identify global disease-specific promoter hypermethylation candidates along bladder cancer progression. DNA obtained from 10 pairs of invasive bladder tumours were profiled vs their respective normal urothelium using differential methylation hybridisation on custom-made CpG arrays (n=12 288 clones). Promoter hypermethylation of 84 clones was simultaneously shown in at least 70% of the tumours. SOX9 was selected for further validation by bisulphite genomic sequencing and methylation-specific polymerase chain reaction in bladder cancer cells (n=11) and primary bladder tumours (n=101). Hypermethylation was observed in bladder cancer cells and associated with lack of gene expression, being restored in vitro by a demethylating agent. In primary bladder tumours, SOX9 hypermethylation was present in 56.4% of the cases. Moreover, SOX9 hypermethylation was significantly associated with tumour grade and overall survival. Thus, this high-throughput epigenomic strategy has served to identify novel hypermethylated candidates in bladder cancer. In vitro analyses supported the role of methylation in silencing SOX9 gene. The association of SOX9 hypermethylation with tumour progression and clinical outcome suggests its relevant clinical implications at stratifying patients affected with bladder cancer.

AB - CpG island arrays represent a high-throughput epigenomic discovery platform to identify global disease-specific promoter hypermethylation candidates along bladder cancer progression. DNA obtained from 10 pairs of invasive bladder tumours were profiled vs their respective normal urothelium using differential methylation hybridisation on custom-made CpG arrays (n=12 288 clones). Promoter hypermethylation of 84 clones was simultaneously shown in at least 70% of the tumours. SOX9 was selected for further validation by bisulphite genomic sequencing and methylation-specific polymerase chain reaction in bladder cancer cells (n=11) and primary bladder tumours (n=101). Hypermethylation was observed in bladder cancer cells and associated with lack of gene expression, being restored in vitro by a demethylating agent. In primary bladder tumours, SOX9 hypermethylation was present in 56.4% of the cases. Moreover, SOX9 hypermethylation was significantly associated with tumour grade and overall survival. Thus, this high-throughput epigenomic strategy has served to identify novel hypermethylated candidates in bladder cancer. In vitro analyses supported the role of methylation in silencing SOX9 gene. The association of SOX9 hypermethylation with tumour progression and clinical outcome suggests its relevant clinical implications at stratifying patients affected with bladder cancer.

KW - Bladder cancer

KW - CpG arrays

KW - Methylation

UR - http://www.scopus.com/inward/record.url?scp=38549123030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38549123030&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6604143

DO - 10.1038/sj.bjc.6604143

M3 - Article

VL - 98

SP - 466

EP - 473

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 2

ER -